Fine-Gray analyses define predictors of unsustained MRD negativity. Patients were stratified according to (A) the percentage of CTCs at diagnosis defined per the cutoff ≥0.01%, (B) ISS 3 at baseline, and (C) time to achievement of MRD negativity. Accordingly, MRD was measured after induction (6 months since diagnosis), after ASCT (9 months), after consolidation (12-14 months), or after year 1 of maintenance therapy (24-26 months).